JSLL

Track this name

Jeena Sikho Lifecare Limited

HealthcareHospitalSmall capModerate edge

Track this name

The storyAyurveda capacity rollout

The engine is the hub-and-spoke bed rollout, with occupancy and ARPOB holding steady.

Overall read

7.4/10

Aligned & cheap

The three reads · this quarter

The standing reads · change less often

Moat

Moderate edge

Real but regional moat — pan-India brand depth held back by sub-scale and unproven cycle.

Key variables

5 tracked

lead: Occupancy rate (operational beds)

Occupancy has improved despite rapid bed additions, indicating better utilization of the expanded capacity. Management's focus on ramping toward 70-80% underpins operating leverage.

Walk the talk

Reliable

as of Q1 FY27

JSLL

Track this name

Jeena Sikho Lifecare Limited

HealthcareHospitalSmall cap

Track this name

The storyAyurveda capacity rollout

The engine is the hub-and-spoke bed rollout, with occupancy and ARPOB holding steady.

Overall read

7.4/10

Aligned & cheap

The three reads · this quarter

JSLL

Track this name

Jeena Sikho Lifecare Limited

HealthcareHospitalSmall capModerate edge

Track this name

The storyAyurveda capacity rollout

The engine is the hub-and-spoke bed rollout, with occupancy and ARPOB holding steady.

Overall read

7.4/10

Aligned & cheap

Where it sits

#11/146TOP 8%

Where it sits

The three reads · this quarter

Moat

Moderate edge

Real but regional moat — pan-India brand depth held back by sub-scale and unproven cycle.

Key variables

5 tracked

lead: Occupancy rate (operational beds)

Occupancy has improved despite rapid bed additions, indicating better utilization of the expanded capacity. Management's focus on ramping toward 70-80% underpins operating leverage.

Walk the talk

Reliable

as of Q1 FY27

Growth readSolidbase 25-30% · Rank 33/100

Entero partnership to expand OTC distribution to 1.25 lakh pharmacies, driving product revenue growth.

bear <20%base 25-30%bull >35%

6.2CHEAP

Valuation readUndervaluedpriced 2 days ago

In line with its own history, and the price assumes growth below our base case.

P/E vs own history · in-lineEV/EBITDA vs own history · in-line